Tempest Therapeutics, Inc. (NASDAQ:TPST) Stock Short Interest Report for September

Tempest Therapeutics, Inc. (NASDAQ:TPST) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 608,434 shares, an increase of 73.6% from the September 15th total of 350,415 shares. Based on an average daily trading volume, of 11,203,617 shares, the short-interest ratio is currently 0.1 days. Approximately 5.6% of the shares of the company are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Tempest Therapeutics stock. Squarepoint Ops LLC purchased a new position in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 30,900 shares of the company’s stock, valued at approximately $34,000. Squarepoint Ops LLC owned 0.19% of Tempest Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 22.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on TPST. Wall Street Zen raised Tempest Therapeutics to a “sell” rating in a report on Saturday, October 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Friday, October 9th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Tempest Therapeutics presently has a consensus rating of “Reduce”.

Tempest Therapeutics Price Performance

Shares of TPST traded up $0.01 during midday trading on Thursday, hitting $0.65. 81,732 shares of the company traded hands, compared to its average volume of 952,149. The stock has a 50-day moving average of $0.94 and a 200-day moving average of $1.27. Tempest Therapeutics has a one year low of $0.62 and a one year high of $11.98. The firm has a market cap of $10.91 million, a P/E ratio of -0.15 and a beta of -1.73.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). Sell-side analysts forecast that Tempest Therapeutics will post -0.83 EPS for the current fiscal year.

About Tempest Therapeutics

Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s research combines tumor-targeted immune activation with approaches designed to disrupt tumor metabolism, with the goal of stimulating the immune system within the tumor microenvironment while limiting effects on healthy tissue.

Tempest’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα).